Publication: Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.
Loading...
Identifiers
Publication date
Advisors
Journal Title
Journal ISSN
Volume Title
Publishers
American Association for Cancer Research (AACR)
Abstract
T and NK lymphocytes express CD137 (4-1BB), a costimulatory receptor of the TNFR family whose function is exploitable for cancer immunotherapy. Mitochondria regulate the function and survival of T lymphocytes. Herein, we show that CD137 costimulation provided by agonist mAb and CD137L (4-1BBL) induced mitochondria enlargement that resulted in enhanced mitochondrial mass and transmembrane potential in human and mouse CD8+ T cells. Such mitochondrial changes increased T-cell respiratory capacities and were critically dependent on mitochondrial fusion protein OPA-1 expression. Mass and function of mitochondria in tumor-reactive CD8+ T cells from cancer-bearing mice were invigorated by agonist mAb to CD137, whereas mitochondrial baseline mass and function were depressed in CD137-deficient tumor reactive T cells. Tumor rejection induced by the synergistic combination of adoptive T-cell therapy and agonistic anti-CD137 was critically dependent on OPA-1 expression in transferred CD8+ T cells. Moreover, stimulation of CD137 with CD137 mAb in short-term cultures of human tumor-infiltrating lymphocytes led to mitochondria enlargement and increased transmembrane potential. Collectively, these data point to a critical link between mitochondrial morphology and function and enhanced antitumor effector activity upon CD137 costimulation of T cells. Cancer Immunol Res; 6(7); 798-811. ©2018 AACR.
Description
Keywords
MeSH Terms
4-1BB Ligand Animals Biomarkers CD8-Positive T-Lymphocytes Cytokines Cytotoxicity, Immunologic Female Gene Silencing Humans Lymphocytes, Tumor-Infiltrating Melanoma, Experimental Membrane Potential, Mitochondrial Mice Mice, Knockout Mitochondria Neoplasms RNA, Small Interfering T-Lymphocytes Tumor Microenvironment
DeCS Terms
Bibliographic citation
Cancer Immunol Res . 2018 Jul;6(7):798-811







